SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

SEQENS is dedicated to offering sustainable and advanced cosmetic solutions to shape the future of personal care with its customers and partners.

The group is set to launch PeptiCode™ HP-9, the first European biotech Hexapeptide-9, developed through the PeptiCode™ biotechnology platform based in Nîmes, France. This platform specializes in various microorganisms’ optimization – such as bacteria, yeast, and microalgae – through strain engineering and fermentation technologies to unlock access to sustainable and innovative naturally-derived peptides.

PeptiCode™ HP-9 is created via precision fermentation, harnessing the power of an optimised microorganism to synthetise a pure, 100% natural origin and bio-identical hexapeptide-9. SEQENS’ process complies with the principles of Green Engineering and ensures high performance and optimal peptide stability without using TFA (trifluoroacetic acid) or PFAS (per- and polyfluoroalkyl substances) during production.

This versatile product is designed for new sustainable anti-aging formulations, as it acts as a signal peptide to boost collagen synthesis. Easy to use and interchangeable with its synthetic counterpart, PeptiCode™ HP-9 is a drop-in replacement. It offers the advantage of avoiding chemical synthesis, while guaranteeing a high-performance, environmentally friendly product.

SEQENS will exhibit at inCosmetics Global 2026 in Paris. Visit us at stand #3Q48 to discover PeptiCode™ HP-9 and the PeptiCode™ platform, designed to develop innovative peptides that contribute to a more sustainable, biotechnology-focused future, meeting the needs of next-generation beauty and personal care products.